[No abstract available]474233242Moll, J.H.M., Haslock, I., MacRae, I., Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's Psease, the intestinal arthropathies, and Behcet's syndrome (1974) Medicine, 53, pp. 343-364Braun, J., Sieper, J., (2002) Building consensus on nomenclature and disease classification for ankylosing spondylitis: Results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002. Ann Rheum Dis 61(Supl. III):61-7Dougados, M., van der Linden, S., Juhlin, R., The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy (1991) Arthritis Rheum, 34, pp. 1218-1227Van der Linden, S., Van der Heijde, D., Ankylosing spondylitis: Clinical features (1998) Rheum Dis Clin North Am, 24, pp. 663-676Calin, A., Elswood, J., Rigg, S., Skevington, S.M., Ankylosing spondylitis - An analytical review of 1,500 patients: The changing pattern of the disease (1988) J Rheumatol, 15, pp. 1234-1238Reveille, J.D., Ball, E.J., Khan, M.A., HLA-B27 and genetic predisposing factors in spondyloarthropathies (2001) Curr Opin Rheumatol, 13, pp. 265-272Sampaio-Barros, P.D., Bertolo, M.B., Kraemer, M.H., Primary ankylosing spondylitis: Patterns of disease in a Brazilian population of 147 patients (2001) J Rheumatol, 28, pp. 560-565Wang SW, Davis JC Jr.: Clinical aspects of ankylosing spondylitis. In: Weisman MH, Reveille JD, van der Heijde D (eds). Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby Elsevier, 2006;145-53Van der Linden, S., Valkenburg, H.A., Cats, A., Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria (1984) Arthritis Rheum, 27, pp. 361-368Van der Heijde D, Landewe R: Assessment of disease activity, function, and quality of life. In: Weisman MH, Reveille JD, van der Heijde D (eds). Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby Elsevier, 2006206-13Braun J, Baraliakos X: Imaging in ankylosing spondylitis. In: Weisman MH, Reveille JD, van der Heijde D (eds). Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby Elsevier, 2006;187-204Garrett, S., Jenkinson, T., Kennedy, L.G., Whitelock, H., Gaisford, P., Calin, A., A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index (1994) J Rheumatol, 21, pp. 2286-2291Cusmanich, K.G., (2006) Validação para a língua portuguesa dos instrumentos de avalição de índice funcional e índice de atividade de doença em pacientes com espondilite anquilosante, , Dissertação de Mestrado em Ciências, Faculdade de Medicina da Universidade de São Paulo. Banco de Tese CapesCalin, A., Garrett, S., Whitelock, H., A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index (1994) J Rheumatol, 21, pp. 2281-2285Shinjo, S.K., Goncalves, R., Kowalski, S., Goncalves, C.R., Brazilian-Portuguese version of the Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) in patients with ankylosing spondylitis: A translation, cross-cultural adaptation, and validation (2007) Clin Rheumatol, 26, pp. 1254-1258Dagfιnrud, H., Kvien, T.K., Hagen, K.B., The Cochrane review of physiotherapy interventions for ankylosing spondylitis (2005) J Rheumatol, 32, pp. 1899-1906Clegg, D.O., Treatment of ankylosing spondylitis (2006) J Rheumatol, 33 (SUPL. 78), pp. 24-31Van der Heijde, D., Baraf, H.S., Ramos-Remus, C., Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study (2005) Arthritis Rheum, 52, pp. 1205-1215Barkhuizen, A., Steinfeld, S., Robbins, J., West, C., Coombs, J., Zwillich, S., Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis (2006) J Rheumatol, 33, pp. 1805-1812Wanders, Van der Heijde D, Landewé R, et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756-65, 2005Ward, M.M., Prospects for disease modification in ankylosing spondylitis: Do nonsteroidal antiinflammatory drugs do more than treat symptoms? (2005) Arthritis Rheum, 52, pp. 1634-1636Dougados, M., Dujkmans, B., Khan, M., Maksymowych, W., Van der Linden, S., Brandt, J., Conventional treatments for ankylosing spondylitis (2002) Ann Rheum Dis, 61 (SUPL. III), pp. 40-50Peters, N.D., Ejstrup, L., Intravenous methylprednisolone pulse therapy in ankylosing spondylitis (1992) Scand J Rheumatol, 21, pp. 134-138Braun, J., Bollow, M., Seyrekbasan, F., Computed tomography guided corticosteroid injection of sacroliac joint in patients with spondyloarthropathy with sacroiliitis: Clinical outcome and followup by dynamic magnetic resonance imaging (1996) J Rheumatol, 23, pp. 659-664Gratacós, J., Collado, A., Pons, F., Significant loss of bone mass in patients with early, active, ankylosing spondylitis: A followup study (1999) Arthritis Rheum, 42, pp. 2319-2324Mitra, D., Elvins, D.M., Speden, D.J., Collins, A.J., Prevalence of vertebral compression fractures in mild ankylosing spondylitis and their relationship to bone mineral density (2000) Rheumatology 39-85-9Zochling, J., Van der Heijde, D., Burgos-Vargas, R., ASAS/EULAR recommendations for the management of anklosing spondylitis (2006) Ann Rheum Dis, 65, pp. 442-452Dougados, M., van der Linden, S., Leirisalo-Repo, M., Sulfasalazine in the treatment of spondylarthropathy: A randomized multicenter, double-blind, placebo-controlled study (1995) Arthritis Rheum, 38, pp. 618-627Benitez-del-Castilho, J.M., Garcia-Sanchez, J., Iradier, T., Bañares, A., Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis (2000) Eye, 14, pp. 340-343Chen, J., Liu, C., Sulfasalazine for ankylosing spondylitis (2005) Cochrane Database Syst Rev, 18 (2). , CD004800Sampaio-Barros, P.D., Costallat, L.T.L., Bertolo, M.B., Marques Neto, J.F., Samara, A.M., Methotrexate in the treatment of ankylosing spondylitis (2000) Scand J Rheumatol, 29, pp. 160-162Chen, J., Liu, C., Lin, J., Methotrexate for ankylosing spondylitis (2006) Cochrane Database Syst Rev, 18 (4). , CD004524Akkoc, N., van der Linden, S., Khan, M.A., Ankylosing spondylitis and symptom-modifying vs. disease modifying therapy (2006) Best Pract Res Clin Rheumatol, 20, pp. 539-557Huang, F., Gu, J., Zhao, W., Zhu, J., Zhang, J., Yu, D.T.Y., One year open label trial of thalidomide in ankylosing spondylitis (2002) Arthritis Rheum, 47, pp. 249-254Maksymowych, W.P., Jhangri, G.S., Fitzgerald, A., A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis (2002) Arthritis Rheum, 46, pp. 766-773Van den Bosch, F., Kruithof, E., Baeten, D., Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy (2002) Arthritis Rheum, 46, pp. 755-765Kruithof, E., Van den Bosch, F., Baeten, D., Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: One year follow up (2002) Ann Rheum Dis, 61, pp. 207-212Braun, J., Landewe, R., Hermann, K.-G., Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study (2006) Arthritis Rheum, 54, pp. 1646-1652Braun, J., Brandt, J., Listing, J., Treatment of ankylosing spondylitis with infliximab: A randomized controlled multicentre trial (2002) Lancet, 359, pp. 1187-1193Braun, J., Brandt, J., Listing, J., Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis (2003) Arthritis Rheum, 48, pp. 2224-2233Braun, J., Baraliakos, X., Listing, J., Sieper, J., Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept (2005) Arthritis Rheum, 52, pp. 2447-2451Braun, J., Baraliakos, X., Brandt, J., Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years (2005) Rheumatology, 44, pp. 670-676Baraliakos, X., Listing, J., Brandt, J., Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab (2005) Arthritis Res Ther, 7, pp. R439-R444Baraliakos, X., Listing, J., Rudwaleit, M., Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis (2007) J Rheumatol, 34, pp. 510-515Brandt, J., Khariouzov, A., Listing, J., Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis (2003) Arthritis Rheum, 48, pp. 1667-1675Davis Jr., J.C., van der Heijde, D., Braun, J., Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized controlled trial (2003) Arthritis Rheum, 48, pp. 3230-3236Maksymowych, W.P., Poole, A.R., Hiebert, L., Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis (2005) J Rheumatol, 32, pp. 1911-1917Baraliakos, X., Brandt, J., Listing, J., Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data (2005) Arthritis Rheum, 53, pp. 856-863Davis, J.C., Van der Heijde, D., Braun, J., Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks (2005) Ann Rheum Dis, 64, pp. 1557-1562Van der Heijde, D., Da Silva, J.C., Dougados, M., Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis (2006) Ann Rheum Dis, 65, pp. 1572-1577Van der Heijde, D., Kivitz, A., Schiff, M.H., Efficacy and safety of adalimumab in patients with ankylosing spondylitis (2006) Arthritis Rheum, 54, pp. 2136-2146Haibel, H., Rudwaleit, M., Brandt, H.C., Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial (2006) Arthritis Rheum, 54, pp. 678-681Braun, J., Davis, J., Dougados, M., First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis (2006) Ann Rheum Dis, 65, pp. 316-320Carmona, L., Gomez-Reino, J.J., Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER (2006) Arthritis Res Ther, R72. , on behalf of the BIOBADASER GroupRudwaleit, M., Listing, J., Brandt, J., Braun, J., Sieper, J., Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis (2004) Ann Rheum Dis, 63, pp. 665-670Delaunay, C., Farrenq, V., Marini-Portugal, A., Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: Preliminary data (2005) J Rheumatol, 32, pp. 2183-2185Moll, J.M.H., Wright, V., Psoriatic arthritis (1973) Semin Arthritis Rheum, 3, pp. 55-78Gladman, D.D., Antoni, C., Mease, P., Clegg, D.O., Nash, P., Psoriatic arthritis: Epidemiology, clinical features, course, and outcome (2005) Ann Rheum Dis, 64 (SUPL. II), pp. ii14-ii17Griffiths CEM, Camp RDR, Barker JN: Psoriasis. In: Champion RH, Burton JL, Burns DA, et al. Rook/Wilkinson/Ebling Textbook of dermatology. 7a ed. Oxford: Blackwell Science, 2004;35.1-65Espinoza, L.R., Cuellar, M.L., Psoriatic arthritis and spondylitis: A clinical approach (1998) Spondylarthritides, pp. 97-111. , Calin A, Taurog JD editors, Oxford: Oxford University PressMease, P., Goffe, B.S., Diagnosis and treatment of psoriatic arthritis (2005) J Am Acad Dermatol, 52, pp. 1-19Balding, J., Kane, D., Livingstone, W., Cytokine gene polymorphisms: Association with psoriatic arthritis susceptibility and severity (2003) Arthritis Rheum, 48, pp. 1408-1413Sibilia, J., Psoriasis: Skin and joints, same fight? (2006) JEADV, 20 (SUPL. 2), pp. 56-72Veale, D., Ritchlin, C., Fitz Gerald, O., Immunopathology of psoriasis and psoriatic arthritis (2005) Ann Rheum Dis, 65, pp. 26-29Taylor, W., Gladman, D., Helliwell, P., Classification criteria for psoriatic arthritis: Development of new criteria from a large international study (2006) Arthritis Rheum, 54, pp. 2665-2673Khan, M.-F., Chamot, A.-M., SAPHO syndrome (1992) Rheum Dis Clin North Am, 18, pp. 225-246Kavanaugh AF, Ritchlin CT, and the GRAPPA Treatment Guideline Committee: Systematic review of treatment for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 33:1417-21, 2006Greaves, M.W., Weinstein, G.D., Treatment of psoriasis (1995) New Engl J Med, 332, pp. 581-588Gladman, D.D., Effectiveness of psoriatic arthritis therapies (2003) Semin Arthritis Rheum, 33, pp. 29-37Tsankov, N., Kazandjieva, J., Drenovska, K., Drugs in exacerbation and provocation of psoriasis (1998) Clin Dermatol, 16, pp. 333-351Soriano, E.R., McHugH, N.J., Therapies for peripheral joint disease in psoriatic arthritis: A systematic review (2006) J Rheumatol, 33, pp. 1422-1430Espinoza, L.R., Zakraoui, I., Espinoza, C.G., Psoriatic arthritis: Clinical response and side effects to methotrexate therapy (1992) J Rheumatol, 19, pp. 872-877Tilling, L., Townsend, S., David, J., Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis (2006) Clin Drug Investig, 26, pp. 55-62Clegg, D.O., Reda, R.J., Mejias, E., Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A Department of Veterans Affairs Cooperative Study (1996) Arthritis Rheum, 39, pp. 2013-2020Olivieri, I., Salvarani, C., Cantini, F., Therapy with cyclosporine in psoriatic arthritis (1997) Semin Arthritis Rheum, 27, pp. 36-43Spadaro, A., Riccieri, V., Silli-Scavalli, A., Sensis, F., Taccari, E., Zoppini, A., Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study (1995) Clin Exp Rheumatol, 13, pp. 589-593Salvarani, C., Macchioni, P., Olivieri, I., A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis (2001) J Rheumatol, 28, pp. 2274-2282Fraser, A.D., van Kujik, A.W.R., Westhovens, R., A randomised, double-blind, placebo-controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis (2005) Ann Rheum Dis, 64, pp. 859-864Kaltwasser, J.P., Nash, P., Gladman, D., Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial (2004) Arthritis Rheum, 50, pp. 1939-1950Kavanaugh, A., Krueger, G.G., Beutler, A., Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial (2007) Ann Rheum Dis, 66, pp. 498-505Kavanaugh, A., Antoni, C.E., Gladman, D., The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year (2006) Ann Rheum Dis, 65, pp. 1038-1043Mease, P.J., Kivitz, A.J., Burch, F.X., Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression (2004) Arthritis Rheum, 50, pp. 2264-2272Mease, P.J., Kivitz, A.J., Burch, F.X., Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept (2006) J Rheumatol, 33, pp. 712-721Gladman, D.D., Mease, P.J., Ritchlin, C.T., Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial (2007) Arthritis Rheum, 56, pp. 476-488Turkiewicz, A.M., Moreland, L.W., Psoriatic arthritis: Current concepts on pathogenesis-oriented therapeutic options (2007) Arthritis Rheum, 56, pp. 1051-1066